CAMPATH-IH in multiple sclerosis.
In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-IH which targets the CD52 antigen present on lymphocytes and monocytes. There was a substantial reduction in disease activity as measured by gadoliunium-enhancing lesions on MRI. Encouraged by this result a further se...
Автори: | Moreau, T, Coles, A, Wing, M, Thorpe, J, Miller, D, Moseley, I, Issacs, J, Hale, G, Clayton, D, Scolding, N, Waldmann, H, Compston, A |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
1996
|
Схожі ресурси
Схожі ресурси
-
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.
за авторством: Moreau, T, та інші
Опубліковано: (1994) -
Inflammation, demyelination, and axonal degeneration: Three aspects of the pathogenesis of multiple sclerosis revealed by campath-1H treatment
за авторством: Coles, A, та інші
Опубліковано: (2003) -
Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
за авторством: Calne, R, та інші
Опубліковано: (1999) -
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.
за авторством: Moreau, T, та інші
Опубліковано: (1996) -
CAMPATH: from concept to clinic.
за авторством: Waldmann, H, та інші
Опубліковано: (2005)